Y-39983

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H16N4O.ClH
Molecular Weight	316.785
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.C[C@@H](N)C1=CC=C(C=C1)C(=O)NC2=C3C=CNC3=NC=C2

InChI

InChIKey=IILQESWQPZIAGP-HNCPQSOCSA-N

InChI=1S/C16H16N4O.ClH/c1-10(17)11-2-4-12(5-3-11)16(21)20-14-7-9-19-15-13(14)6-8-18-15;/h2-10H,17H2,1H3,(H2,18,19,20,21);1H/t10-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H16N4O
Molecular Weight	280.3244
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://adisinsight.springer.com/drugs/800023536https://www.ncbi.nlm.nih.gov/pubmed/23258382
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20434334 | https://www.ncbi.nlm.nih.gov/pubmed/24684843 | https://www.ncbi.nlm.nih.gov/pubmed/24008512 | https://www.ncbi.nlm.nih.gov/pubmed/21667088

Y-33075 is potent and selective ROCK (Rho-associated coiled-coil-forming protein kinase) inhibitor, developed by Yoshitomi Pharmaceutical Industries for encephalomyelitis treatment. In rabbits and in monkeys, Y-33075 lowers IOP in a dose-dependent fashion. An increase in regenerating axons of RGCs in 100 mM Y-33075-treated eyes is observed compared with saline-treated eyes. Y-33075 dose-dependently increases the number of RGCs with regenerating axons. Both Y-33075 induces a concentration-dependent relaxation in rabbit ciliary arteries precontracted with a high-potassium (high-K) solution. The amplitude of relaxation induced by Y-33075 is not affected by either 100 μM N (G)-nitro-L: -arginine methyl ester (L: -NAME) or 10 μM indomethacin. In Ca2 -free solution, Y-27632 and Y-39983 significantly inhibit the transient contraction of ciliary arteries induced by 10 μM histamine. However, neither Y-27632 nor Y-39983 affects the elevation of [Ca2 ](i) induced by high-K solution and histamine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Rho-associated protein kinase 1 20 Target ID: CHEMBL3231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20434334	Inhibitor 8297	30.0 nM [IC50]
Rho-associated protein kinase 2 25 Target ID: CHEMBL2973 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24684843	Inhibitor 8297	58.0 nM [IC50]
Rho-associated protein kinase 7 Target ID: CHEMBL2111459 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17591891	Inhibitor 8297	3.6 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Encephalomyelitis 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24008512	Primary	Basic research	Unknown Approved Use Unknown
Ocular hypertension 50 Sources: http://adisinsight.springer.com/drugs/800023536	Primary	Phase II 1132	Unknown Approved Use Unknown
Open-angle glaucoma 51 Sources: http://adisinsight.springer.com/drugs/800023536	Primary	Phase II 1132	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P001ZQJ	https://www.1pchem.com/search?query=1P001ZQJ
1PlusChem LLC	1P002CKV	https://www.1pchem.com/search?query=1P002CKV
AK Scientific	4163AH	https://aksci.com/item_detail.php?cat=4163AH
AK Scientific	8982AA	https://aksci.com/item_detail.php?cat=8982AA
Angene	AGN-PC-0QAFEI	http://www.angenechemical.com/productshow/AGN-PC-0QAFEI.html
Angene	AGN-PC-0RUZDD	http://www.angenechemical.com/productshow/AGN-PC-0RUZDD.html
AstaTech	C15092	http://astatechinc.com/CPSResult.php?CRNO=C15092
BLD Pharm	BD237580	http://www.bldpharm.com/search/Search.html?keyword=BD237580
BLD Pharm	BD630514	http://www.bldpharm.com/search/Search.html?keyword=BD630514
BOC Sciences	173897-44-4	http://www.bocsci.com/description.asp?cas=173897-44-4
Chem Scene	CS-0096	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0096
Chem Scene	CS-0097	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0097
Lab Network	LN01343361	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343361
Lab Network	LN01343362	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343362
MedChem Express	HY-10067	https://www.medchemexpress.com/search.html?q=HY-10067&ft=&fa=&fp=
MedChem Express	HY-10069	https://www.medchemexpress.com/search.html?q=HY-10069&ft=&fa=&fp=
MolPort	MolPort-023-333-598	https://www.molport.com/shop/molecule-link/MolPort-023-333-598
MolPort	MolPort-039-139-849	https://www.molport.com/shop/molecule-link/MolPort-039-139-849
MuseChem	I002265	https://www.musechem.com/product/I002265.html
MuseChem	I010115	https://www.musechem.com/product/I010115.html
Selleck Chemicals	S7935	http://www.selleckchem.com/search.html?searchDTO.searchParam=S7935
Toronto Research Chemicals	A594890	https://www.trc-canada.com/product-detail/?CatNum=A594890
Toronto Research Chemicals	T704103	https://www.trc-canada.com/product-detail/?CatNum=T704103
Wonderchem	WD05E9A	http://www.wonder-chem.com/search.html?text=WD05E9A
eMolecules	295311068	https://orderbb.emolecules.com/search/#?query=295311068
eMolecules	295311070	https://orderbb.emolecules.com/search/#?query=295311070
eMolecules	300722846	https://orderbb.emolecules.com/search/#?query=300722846
eMolecules	44469308	https://orderbb.emolecules.com/search/#?query=44469308
eMolecules	44811826	https://orderbb.emolecules.com/search/#?query=44811826
mcule	MCULE-8567762364	https://mcule.com/MCULE-8567762364/

PubMed

Title	Date	PubMed
A novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats.	2007 May	17359977
Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK.	2009 Jun	19456252
Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries.	2011 Jul	21667088
Y-39983 downregulates RhoA/Rho-associated kinase expression during its promotion of axonal regeneration.	2013 Mar	23258382

Patents

Sample Use Guides

In Vivo Use Guide

Senju Pharmaceuticals completed a phase II trial that evaluated the dose-response relationship of ocular hypotensive efficacy and safety of Y 39983 at concentrations ranging from 0.003%, 0.01%, 0.03% or Y 39983 vehicle control given twice a day for 4 weeks in patients with primary open angle glaucoma or ocular hypertension (UMIN000018866)

Route of Administration: Topical

In Vitro Use Guide

In medium containing 1 uM Y-39983, HUVECs exhibited contraction. The morphologic changes in HUVECs were reversible and had nearly recovered by 1 hour after removal of Y-39983

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:23:31 GMT 2023` Edited by `admin` on `Fri Dec 15 16:23:31 GMT 2023`
Record UNII	3304VH0J6B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Y-39983

Common Name

English

BENZAMIDE, 4-((1R)-1-AMINOETHYL)-N-1H-PYRROLO(2,3-B)PYRIDIN-4-YL-, HYDROCHLORIDE (1:1)

Systematic Name

English

Code System Code Type Description

ChEMBL

CHEMBL571948